EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V

Changchang Lu, Lu Zou, Qiaoli Wang, Mengna Sun, Tianyu Shi, Shuang Xu, Fanyan Meng, Juan Du

Biomolecules and Biomedicine · 2024

DOI: 10.17305/bb.2024.10431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Changchang Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, T-Lymphocytes, Proto-Oncogene Proteins p21(ras), CD3 Complex. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is one of the most frequent oncogenes. However, there are limited treatment options due to its intracellular expression. To address this, we developed a novel bispecific T-cell engager (BiTE) antibody targeting HLA-A2/KRAS G12V complex and CD3 (HLA-G12V/CD3 BiTE). We examined its specific binding to tumor cells and T cells, as well as its anti-tumor effects in vivo. HLA-G12V/CD3 BiTE was expressed in Escherichia coli and its binding affinities to CD3 and HLA-A2/KRAS G12V were measured by flow cytometry, along with T-cell activation. In a xenograft pancreatic tumor model, the HLA-G12V/CD3 BiTE's anti-tumor effects were assessed through tumor growth, survival time, and safety. Our results demonstrated specific binding of HLA-G12V/CD3 BiTE to tumor cells with an HLA-A2/KRAS G12V mutation and T cells. The HLA-G12V/CD3 BiTE also activated T-cells in the presence of tumor cells in vitro. HLA-G12V/CD3 BiTE in vivo testing showed delayed tumor growth without severe toxicity to major organs and prolonged mouse survival. This study highlights the potential of constructing BiTEs recognizing an HLA-peptide complex and providing a novel therapy for cancer treatment targeting the intracellular tumor antigen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificT-LymphocytesProto-Oncogene Proteins p21(ras)CD3 ComplexHumansAnimalsMicePancreatic NeoplasmsXenograft Model Antitumor AssaysCell Line, TumorHLA-A2 AntigenFemale

Substanzen

Antibodies, BispecificProto-Oncogene Proteins p21(ras)CD3 ComplexKRAS protein, humanHLA-A2 Antigen

Autor:innen und Institutionen

  • Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; Institute of Translational Medicine, Zhejiang University, Han…
  • Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China; The Comprehensive Cancer Center of Nanjing Drum Tower Hospita…
  • The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China.

Zitieren

APA

Lu, C., Zou, L., Wang, Q., Sun, M., Shi, T., Xu, S., Meng, F., & Du, J. (2024). Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10431

Vancouver

Lu C, Zou L, Wang Q, Sun M, Shi T, Xu S, et al. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10431

BibTeX
@article{Lu2024,
  author = {Lu, Changchang and Zou, Lu and Wang, Qiaoli and Sun, Mengna and Shi, Tianyu and Xu, Shuang and Meng, Fanyan and Du, Juan},
  title = {Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  doi = {10.17305/bb.2024.10431}
}
Kostenlos starten →